|Last Price||Today's Change||52-Week Range||Trading Volume|
|50.81||-0.40 (-0.78%)||31.85 - 53.68||2.3 million (Below Avg)|
Market data as of 12:23PM 12/10/13. Quotes are delayed by at least 15 min.
Four-Year Data from Phase 3 DASISION Trial Comparing Sprycel® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Presented at Annual Meeting of the American Society of Hematology
12/09/2013 6:30 PM ET